Seres Therapeutics (MCRB) Receives Analyst Rating

Seres Therapeutics (MCRB) : The consensus on Seres Therapeutics (MCRB) based on 6 analyst recommendation on the company stock is 1.33, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Seres Therapeutics (MCRB) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $23 and the lowest price target forecast is $12. The average forecast of all the analysts is $15.5 and the expected standard deviation is $5.2.


Also, In a research note released to the investors, Bank of America downgrades its rating on Seres Therapeutics (NASDAQ:MCRB).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The rating by the firm was issued on August 1, 2016.

Seres Therapeutics (NASDAQ:MCRB): After opening at $11.9, the stock dipped to an intraday low of $11.88 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $12.61 and the buying power remained strong till the end. The stock closed at $12.48 for the day, a gain of 5.76% for the day session. The total traded volume was 548,013. The stocks close on the previous trading day was $11.8.

Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. Its SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *